Zenas BioPharma, Inc.

ZBIO · XNCM · Biotechnology · United States

Market Capitalization1.13B USD

Trailing P/E1.63 USD

52-Week Change61.73 USD

Forward Annual Dividend Yield0.04%

Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company focuses on advancing innovative immunology-based treatments, with a strong commitment to addressing diseases characterized by significant unmet medical needs. Zenas BioPharma's pipeline features lead candidates such as obexelimab, a bifunctional monoclonal antibody targeting CD19 and FcγRIIb, and orelabrutinib, a highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in Phase 3 development for multiple sclerosis and other autoimmune indications. The firm's portfolio also includes other monoclonal antibodies and immunomodulators under investigation for disorders like immunoglobulin G4-related disease and systemic lupus erythematosus. Guided by values emphasizing innovation, urgency, and patient impact, Zenas BioPharma operates with the aim of bringing novel treatment options to patients, their families, and caregivers, ultimately seeking to improve quality of life and redefine therapeutic possibilities in the autoimmune sector.

Industry

Biotechnology

Healthcare sector · United States

Stories

Structural patterns identified in Zenas BioPharma, Inc.

No stories identified yet.

Key Metrics

Market Capitalization

1.13BUSD

NormalMar 25, 2026

Trailing P/E

1.63USD

BelowNormalMar 25, 2026

Revenue (TTM)

10.00MUSD

NormalMar 25, 2026

Coordination

Placeholder CorpCoordination

Example HoldingsCoordination

Sample IncCoordination

Supply Chain

Vaccine Supply Chain

The vaccine supply chain is shaped by three structural constraints that most manufacturing industries never encounter: cold chain integrity requires unbroken refrigeration from manufacturing to injection — with some products requiring ultra-cold storage at -70°C, biological manufacturing variability means vaccines are grown in living systems where yields fluctuate batch to batch and cannot be precisely controlled, and regulatory lot release requires every batch to be independently tested and approved before distribution — a process that takes weeks and cannot be skipped or parallelized.